Grace Therapeutics Q1 net loss $15.8M, $13.5M IPR&D impairment

Grace Therapeutics, Inc.

2027-Q1 EPS reported -$0.91

Net loss $15.8M ($0.91/share) vs $3.4M ($0.21) YoY; includes $13.5M impairment of GTx-101/102 IPR&D.
Cash $22.2M as of Aug 11, 2026; runway through end of 2028; $10M private placement announced.
FDA Type A meeting minutes received; CRL items are CMC/non-clinical, no clinical safety/efficacy issues.
Dual-source manufacturing: tech transfer to second U.S. CMO underway; NDA resubmission timing depends on site readiness.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.